Background: A recent genome-wide association study in German Shepherd dogs
| INTRODUCTION
Inflammatory bowel disease (IBD) in humans is an idiopathic chronic relapsing disease, 1 hypothesized to involve the interplay of 4 key components: (1) genetic susceptibility, (2) environmental risk factors, (3) intestinal dysbiosis, and (4) altered gastrointestinal (GI) mucosal immune response. 2 Inflammatory bowel disease in humans is comprised of Crohn's disease (CD) and ulcerative colitis (UC), which differ in pathogenesis, localization of disease within the GI tract, and therapeutic management. 2 The identification of inflammatory mediators by genome-wide association studies (GWAS) has enabled the development of specific treatment options for either CD or UC, with efficacious biologic drugs such as infliximab (anti tumor necrosis factor-alpha antibody) in CD [3] [4] [5] and tofacitinib 6, 7 (a JAK kinase inhibitor that decreases secretion of several Th2 cytokines) in UC.
Similar to IBD in humans, chronic enteropathy (CE) in dogs also is a chronic relapsing disease and the pathogenesis is considered to involve the same 4 key components. 8 Chronic enteropathy is predominantly treated with corticosteroids, 9,10 but up to 50% of dogs will develop resistance, clinically important adverse effects, or both, which ultimately leads to euthanasia. 11 It is therefore critical to develop more specific and efficacious treatment for long-term management of dogs with CE. In the United Kingdom, German Shepherd dogs (GSDs)
are at a significantly higher risk of developing CE compared with mixed breed dogs. 12 One recent study identified several single nucleotide polymorphisms in IL-4, IL-5, and IL-13 that were significantly associated with CE in GSDs. 13 This novel finding is reminiscent of the strong Th2 cytokine predominance found in the intestinal mucosa in humans with UC and suggests that Th2 cytokines also might be implicated in the pathogenesis of CE in GSDs. Previous studies investigating the mucosal cytokine profile in dogs with CE have not definitively determined a Th1, Th2, or Th17 predominance. 14, 15 However, many of these studies were performed on few samples and utilized different molecular methods, which makes it difficult to directly compare results among studies. Also, these studies largely included different breeds of dogs, and because of limited sample sizes, subanalysis of cytokine expression for each breed was not performed. Inflammatory profiles may differ among breeds of dogs presenting with CE, because of different etiopathogeneses.
We aimed to determine if mRNA expression of the Th2 cytokines, IL-13 and IL-33 was altered in the duodenal mucosa of GSDs with CE compared to non-GSDs with CE and healthy Beagle dogs, using a novel RNA in situ hybridization (ISH) technology, RNAscope. The advantages of RNAscope include a unique patented probe (Z probe) design which increases amplification of target-specific signals but not background noise. 16 Interleukin-13 and IL-33 were chosen for further investigation, because recent results of GWAS in GSDs with CE implicated the IL-13
gene, and studies in human and mouse models of IBD have highlighted the importance of IL-33, which has not been extensively investigated to date in dogs with CE. We hoped to further unravel the pathogenesis of CE in GSDs, which might help in the development of novel therapeutic modalities, as is already the case for UC in humans.
| MATERIALS AND METHODS

| Study design
We performed a retrospective study using archived paraffin-embedded 10%
formalin-fixed duodenal biopsy samples from dogs with CE referred to Bristol Veterinary School. Tissue specimens from 3 groups of dogs were studied:
GSD CE (N = 10), non-GSD CE (N = 10), and healthy controls (N = 8) from a population of healthy Beagle dogs at the Iowa State University.
| Retrospective study criteria for case selection
The histopathology archive at the Bristol Veterinary School was searched for GSD and non-GSD cases with a histologic diagnosis of chronic inflammatory enteropathy. All medical records were then reviewed by 1 of the authors (Aarti Kathrani 
| Control dogs
The research colony at the Iowa State University (8 female spayed Beagle dogs, 2 years of age) was used to obtain intestinal biopsy samples from healthy control dogs. The dogs were assessed as clinically healthy, and had a CBC, serum biochemistry profile, urinalysis, and fecal parasitology performed, all of which were normal. Duodenal biopsy samples were collected from control dogs during upper GI endoscopy. 
| RNA in situ hybridization
| Ethical considerations
Archived paraffin-embedded duodenal biopsy samples were used and the University of Bristol granted ethical approval for the study (VIN/18/014). Iowa State University granted ethical approval for the use of paraffin-embedded duodenal biopsy samples from healthy colony Beagle dogs (9-17-8605-K).
| Data analysis and statistics
The Shapiro-Wilk and Levene's tests were used to assess the assumptions of normality and homoscedasticity, respectively. A 1-way analysis of variance (ANOVA) was performed to assess for any significant differences in average mRNA expression scores of IL-13 and IL-33 in the different mucosal compartments (villus, subvillus, epithelial, and lamina propria) among the 3 groups (GSD CE, non-GSD CE, and healthy). Post hoc pairwise comparisons then were performed using Tukey's honest significant difference test. Significance was defined as P < .05. Statistical analyses were performed using IBM SPSS Statistics version 24 and R Statistical software, version 3.5.1.
3 | RESULTS
| Dogs
Ten GSDs with CE were included in the study: 5 female neutered and 5 male neutered dogs, with a median age of 7.2 years and a range of included; all were female spayed and 2 years of age.
There were no significant differences in age or CCEAI between the GSD CE and non-GSD CE groups (P > .22).
| Interleukin-13 mRNA
One-way ANOVA comparing IL-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores among GSDs with CE, non-GSDs with CE, and healthy dogs showed a significant difference for all 4 distribution scores among the 3 groups (P < .03).
Post hoc analysis using the Tukey's Honest Significant Difference test showed that GSDs with CE had significantly lower average IL-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria expression scores compared to non-GSDs with CE (mean ± SD): (1) villus score: GSD CE, 0.43 ± 0.30; non-GSD CE, 0.81 ± 0.37; P = .03; (2) subvillus score: GSD CE, 0.06 ± 0.11; non-GSD CE, 0.33 ± 0.26; P = .04; (3) epithelial score: GSD CE, 0.07 ± 0.19; non-GSD CE, 0.44 ± 0.47; P = .03; and (4) lamina propria score: GSD CE, 0.43 ± 0.31; non-GSD CE, 0.82 ± 0.24; P = .009 (Table 1 and Figure 1 ).
In addition, GSDs with CE had significantly lower duodenal subvillus and lamina propria average expression scores compared to healthy control dogs: (1) subvillus score: GSD CE, 0.06 ± 0.11; healthy 0.40 ± 0.30; P = .01 and (2) lamina propria score: GSD CE, 0.43 ± 0.31; healthy, 0.81 ± 0.25; P = .02 (Table 1 ; Figures 1 and 2) .
Lastly, the post hoc analysis showed that non-GSDs with CE had significantly higher IL-13 mRNA duodenal epithelial average expression score compared to healthy control dogs: non-GSD CE, 0.44 ± 0.47; healthy, 0.05 ± 0.09; P = .03 (Table 1 and Figure 1 ).
| Interleukin-33 mRNA
One-way ANOVA comparing average IL-33 mRNA duodenal villus, subvillus, epithelial, and lamina propria expression scores among GSDs with CE, non-GSDs with CE, and healthy dogs showed a significant difference for subvillus, epithelial, and lamina propria expression scores among the 3 groups (P < .01).
Post hoc analysis using Tukey's Honest Significant Difference test
showed that GSDs with CE had significantly lower average IL-33 mRNA duodenal subvillus, epithelial and lamina propria expression scores compared to non-GSDs with CE and lower average subvillus and epithelial expression scores compared to healthy control dogs:
GSD CE vs Non-GSD CE: (1) subvillus score: GSD CE, 0.37 ± 0.49; non-GSD CE, 1.36 ± 0.49; P < .001; (2) epithelial score: GSD CE, 0.50 ± 0.83; non-GSD CE, 1.58 ± 0.86; P = .01; (3) lamina propria score: GSD CE, 0.73 ± 0.49; non-GSD CE, 1.35 ± 0.39; P = .007 (Table 2 ). For GSD CE versus healthy: (1) subvillus score: GSD CE, 0.37 ± 0.49; healthy, 1.37 ± 0.42; P < .001; (2) epithelial score: GSD CE, 0.50 ± 0.83; healthy, 1.84 ± 0.53; P = .003 (Table 2 ; Figures 3 and 4 ). There were no significant differences in IL-33 mRNA expression between non-GSDs with CE and healthy control dogs (Table 2 ).
| DISCUSSION
Cytokines in the Th2 pathway have been implicated in the pathogenesis of UC, a subtype of IBD in humans. 19 Similarly, a recent GWAS has implicated the possible role of Th2 cytokines in the pathogenesis of Significance was defined in bold as P < .05.
F I G U R E 1 Individual scatter dot plot
showing interleukin (IL)-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores for healthy Beagle control dogs (N = 8), German Shepherd dogs (GSDs) with chronic enteropathy (CE) (N = 10), and non-GSDs with CE (N = 10). Line represents mean with SD. There were significant differences in IL-13 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores between GSDs with CE and non-GSDs with CE, P < .04. There also were significant differences in IL-13 mRNA duodenal subvillus and lamina propria average expression scores between GSDs with CE and healthy Beagle control dogs, P < .02; and epithelial average expression score between non-GSDs with CE and healthy Beagle control dogs, P = .03 CE in GSDs. 13 Therefore, we aimed to determine whether the mRNA expression of 2 Th2 cytokines, IL-13 and IL-33, was altered in the duodenal mucosa of GSDs with CE compared to non-GSDs with CE and healthy control dogs. Our study showed that GSDs with CE had significantly decreased IL-13 and IL-33 mRNA expression in the duodenal mucosa compared with non-GSDs with CE and healthy dogs.
Interleukin-33 functions both as a cytokine and as a nuclear transcription factor. 20 It activates both the innate and adaptive immune Significance was defined in bold as P < .05.
F I G U R E 3 Individual scatter dot plot
showing interleukin (IL)-33 mRNA duodenal villus, subvillus, epithelial, and lamina propria average expression scores in healthy Beagle control dogs (N = 8), German Shepherd dogs (GSDs) with chronic enteropathy (CE) (N = 10), and non-GSDs with CE (N = 10). Line represents mean with SD. There were significant differences in IL-33 mRNA duodenal subvillus, epithelial, and lamina propria average expression scores between GSDs with CE and non-GSDs with CE, P < .02. There were also significant differences in IL-33 mRNA duodenal subvillus and epithelial average expression scores between GSDs with CE and healthy Beagle dogs, P < .004 system and is a critical cytokine for Th2-mediated host defense, as well as playing a key role in regulating immune responses in barrier tissues such as the intestine. 20, 21 Interleukin-33 also functions as an alarmin and is released by epithelial and endothelial cells in response to cell injury and necrosis. 20 Therefore, IL-33 acts as an important early indicator for the immune system when a breach in mucosal barrier function occurs. 22 Also, because IL-33 promotes an early Th2 immune response, it helps to regulate Th1 immune responses and prevent autoimmunity. 23, 24 Interleukin-33 has been shown to influence both T regulatory cells and Th17 cells to decrease inflammation and protect the intestinal mucosa from self-inflicted injury. 21 Studies suggest that nuclear IL-33 can sequester nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), thereby decreasing subsequent NF-κB-generated proinflammatory signaling. 25 Interleukin-33 also may be involved in mucus production, because mice given exogenous IL-33 in vivo produce more colonic mucin. 26 A recent study also suggests a protective role for IL-33 in epithelial regeneration and intestinal mucosal wound healing. 27 The protective effects of IL-33 mainly have been demonstrated in mouse models. Several studies have shown that IL-33 knockout mice are more susceptible to dextran sodium sulfate (DSS) administration compared to wild-type mice. [28] [29] [30] Interleukin-33 treatment ameliorated colitis in DSS, 2,4,6-trinitrobenzenesulfonic acid, and peritoneal cavity cell transfer models. 31 Interleukin-33 treatment also increased B and T regulatory cell responses, suppressed Th17 responses, and switched Th1 to Th2 response in DSS-induced colitis. 32, 33 Interleukin-33 has been shown to promote IgA production by B cells, which is important for maintaining intestinal homeostasis. 28 Interleukin-33 deficient mice also developed intestinal dysbiosis, which was characterized by increased numbers of mucolytic and colitogenic bacteria. 28 Therefore, because IL-33 has been shown to be important for gut homeostasis and in ameliorating intestinal inflammation, our study suggests that the significant decrease in IL-33 expression in the duodenal mucosa of GSDs with CE may cause or contribute to the chronic intestinal inflammation seen in this disease. Interestingly, a previous study documented increased NF-κB activity in dogs with CE. 34 Because nuclear IL-33 can sequester NF-κB, leading to decreased proinflammatory signaling, decreased IL-33 mRNA expression in GSDs with CE may result in increased NF-κB activation with a subsequent increase in inflammation.
However, additional studies would be needed to confirm this mechanism for increased NF-κB activation in dogs with CE. Additionally, GSDs with CE previously have been shown to have relatively decreased
IgA production, as well as intestinal dysbiosis. 35, 36 However, the definitive mechanism for these findings is unknown. Our study functional studies would be needed to definitively prove the role of these implicated genes and their consequent effects on other Th2 cytokines in the pathogenesis of CE in GSDs.
Our study did not show a significant difference in duodenal IL-33 mRNA expression scores between non-GSDs with CE and healthy dogs. This finding is in contrast to a previous study, which documented significantly decreased mRNA expression of IL-33 in the duodenum of dogs with food-responsive enteropathy (FRE) compared to healthy Beagle dogs. 37 The lack of significance in our study might be because of the inclusion of different non-GSD breeds of dogs with CE, whereas the previous study contained 7 dogs, each a different non-GSD breed with FRE and only 1 of the dogs in our non-GSD group was the same breed. In addition, our study did not subcategorize dogs with CE into treatment response, histological severity or type of inflammatory infiltrate. Therefore, the heterogeneity of breed, treatment response, and histopathologic severity and type of cellular infiltrate of CE in our non-GSD group may have diluted any significant effects from single breeds, FRE, or histologic type resulting in nonsignificance. Therefore, future studies investigating the etiopathogenesis of CE in dogs should focus on homogenous populations using the same breeds, treatment response, and intestinal histologic type.
Interleukin-13 is a Th2 cytokine that is produced mainly by T cells and natural killer cells. 38 It also has been shown to weaken epithelial barrier function and induce epithelial cell apoptosis and downregulation of tight junction proteins. 39 However, studies have produced ambiguous result with regard to its role in human and mouse models of IBD.
Some studies have documented large amounts of IL-13 in the intestinal epithelium of patients with UC. [40] [41] [42] [43] Interleukin-13 has been suggested to be a cause of inflammation, because UC patients treated with interferon-beta-1a had significantly downregulated IL-13 production. 44 However, other studies have documented significantly decreased IL-13 concentrations in patients with UC compared with controls, with concentrations lower in active UC versus inactive UC. 45, 46 Some earlier studies have described IL-13 as an anti-inflammatory agent in vitro, because it inhibited monocyte secretion of IL-1 beta in a dose-dependent manner. 47 We determined that IL-13 mRNA was significantly decreased in the duodenal mucosa of GSDs with CE compared with non-GSDs with CE and healthy control dogs. A previous GWAS in GSDs with CE implicated polymorphisms in the IL-13 gene. 13 Therefore, our study sug- In conclusion, our study showed that GSDs with CE exhibited decreased expression of IL-13 and IL-33 mRNA in the inflamed duodenal mucosa compared to non-GSDs with CE and healthy Beagle dogs. Further studies are needed to determine the consequences of this decreased expression, such as decreased intestinal IgA production and intestinal dysbiosis, as well as to determine if decreased expression is the cause or an effect of CE in this breed.
